Literature DB >> 19268005

Neurological manifestations of acute intermittent porphyria.

E Pischik1, R Kauppinen.   

Abstract

Acute intermittent porphyria (AIP) is an inherited metabolic disease due to a deficiency of the hydroxymethylbilane synthase in the haem biosynthesis. It manifests with occasional neurovisceral crises due to overproduction of porphyrin precursors such as aminolaevulinic acid (ALA) which is released from the liver to the circulation. The majority of the acute attacks manifest as a combination of abdominal pain, mild mental symptoms and autonomic dysfunction mainly due to vagal insufficiency. However, both acute peripheral neuropathy and encephalopathy may develop if an acute attack proceeds especially due to administration of porphyrinogenic drugs. Acute porphyric neuropathy is predominantly motor and associates with a history of abdominal pain and dysautonomia, CNS involvement and mild hepatopathy. Other features include preservation of achilles reflexes while global hyporeflexia and neuropathic or myalgic pain. The pathogenesis of porphyric neuropathy is complex but overproduction of ALA via direct neurotoxicity, oxidative damage, and modification of glutamatergic release may initiate the neuronal damage. Acute encephalopathy manifests as a combination of mental symptoms, seizures, SIADH, but rarely focal CNS deficits. Posterior reversible encephalopathy syndrome (PRES), which has been found in patients' MRI during an acute attack with severe encephalopathy, could explain the pathogenesis of encephalopathy and seizures in AIP. Neurological manifestations are unspecific and careful interpretation of abnormal excretion of porphyrin precursors should be done before the symptoms can be related to inherited acute porphyrias and not to secondary porphyrinuria. Currently the prognosis of neuropathy and encephalopathy in AIP is good even in severe attacks, but physicians should be aware of a potentially fatal outcome of the disease.

Entities:  

Mesh:

Year:  2009        PMID: 19268005

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  19 in total

1.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 2.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

3.  Blood lead levels, ALAD gene polymorphisms, and mortality.

Authors:  Dana M van Bemmel; Yan Li; Jody McLean; Man-Huei Chang; Nicole F Dowling; Barry Graubard; Preetha Rajaraman
Journal:  Epidemiology       Date:  2011-03       Impact factor: 4.822

Review 4.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

Review 5.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

6.  The clinical importance of early acute hepatic porphyria diagnosis: a national cohort.

Authors:  Yonatan Edel; Rivka Mamet; Sharon Cohen; Daniel Shepshelovich; Assi Levi; Iftach Sagy
Journal:  Intern Emerg Med       Date:  2020-05-06       Impact factor: 3.397

7.  Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study.

Authors:  Mette Christophersen Tollånes; Aasne Karine Aarsand; Sverre Sandberg
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

8.  Acute intermittent porphyria.

Authors:  Kartik Syal; Rashmi Bhatt; Surinder Singh; Anil Ohri
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun

9.  Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome, Accompanied by Prolonged Vasoconstriction.

Authors:  Tadayuki Takata; Kodai Kume; Yohei Kokudo; Kazuyo Ikeda; Masaki Kamada; Tetsuo Touge; Kazushi Deguchi; Tsutomu Masaki
Journal:  Intern Med       Date:  2017-03-17       Impact factor: 1.271

Review 10.  An update of clinical management of acute intermittent porphyria.

Authors:  Elena Pischik; Raili Kauppinen
Journal:  Appl Clin Genet       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.